Rachel Pokorny, PharmD, BCPS, BCOP

The panelists recommend cross-comparing equations, deciding doses with the care team, and watching for patients at high risk of inaccurate estimates when moving chemotherapy dosing from Cockcroft-Gault to eGFR.

Moving from Cockcroft-Gault to race-agnostic estimated glomerular filtration rate (eGFR) for drug dosing is slowed by older trial data, inconsistent package inserts, gaps in education, and the work of updating EHR order sets.